Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly ( LLY 1.09%).

Eli Lilly announced clinical trial results this week for a daily pill to treat obesity and diabetes. Its name is absolutely ...

Chief executive officers from Nvidia Corp., Johnson & Johnson, Eli Lilly & Co., General Electric Co. and SoftBank Group Corp.

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling ...

Which stock rocked the table with a double downgrade? The Investment Committee reveals today's Calls of the Day!

Novo is expanding its direct-to-consumer efforts around its obesity drug Wegovy, partnering with telehealth companies ...

The trial met its primary objectives, showing the pill’s effectiveness in helping patients with Type 2 diabetes achieve ...

Pharmaceutical giant Eli Lilly alleges the companies are selling illegal off-brand versions of its best-selling diabetes and ...

Eli Lilly and Company's orforglipron had good results in Type 2 diabetes trials, potentially becoming the first scalable oral ...